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Several different receptor proteins have been identified that
bind monomeric, oligomeric, or fibrillar forms of amyloid-
(A). “Good” receptors internalize A or promote its transcy-
tosis out of the brain, whereas “bad” receptors bind oligomeric
forms of A that are largely responsible for the synaptic
loss, memory impairments, and neurotoxicity that underlie
Alzheimer disease. Theprionprotein both removesA from the
brain and transduces the toxic actions of A. The clustering of
distinct receptors in cell surface signaling platforms likely
underlies the actions of distinct oligomeric species of A. These
A receptor-signaling platformsprovide opportunities for ther-
apeutic intervention in Alzheimer disease.
Alzheimer disease (AD)2 is characterized pathologically by
the deposition in the brain of the 40–42-amino acid amyloid-
(A) peptide in extracellular plaques and of the microtubule-
binding protein tau in intracellular neurofibrillary tangles. The
amyloid cascade hypothesis, formulated over 20 years ago, pos-
its that A, derived from the proteolytic processing of the amy-
loid precursor protein, is the causative agent in AD pathology
and that neurofibrillary tangles, cell loss, vascular damage, and
dementia follow (1). A recent and critical interpretation of the
existing data concluded that aggregated A acts primarily as a
trigger of other downstream processes, particularly tau aggre-
gation, which mediate neurodegeneration (2). Understanding
the nature of the interaction of A with neurons and other cell
types in the brain is key to a complete understanding of the
pathogenesis of AD. Furthermore, identifying the proteins
involved in the binding of aggregated forms of A and the
downstream cytotoxic signaling pathways that are subse-
quently activated may reveal sites for therapeutic intervention.
In this minireview, we provide an overview of the “bad” recep-
tors involved in the binding and cytotoxic action of A, as well
as the “good” receptors involved in A metabolism and clear-
ance from the brain (Fig. 1, Table 1).More detailed information
on the A receptors and carriers, including the type of A they
bind, the cell type they are expressed on, binding partners, and
downstream targets, is provided in supplemental Table 1.
The Ligand: Multiple Forms of A
Any discussion of receptors has to take into account the
properties of the ligand(s) that binds to that receptor. In the
case of the ligandA, this is complicated by the fact that it exists
in multiple forms from monomers, through dimers, trimers,
and oligomers to protofibrils and fibrils that range in size from
4 kDa to assemblies of100 kDa, and vary in morphology and
conformation (3). A oligomers (AO) appear to be the most
neurotoxic species, triggering various processes that underlie
AD, including synaptic dysfunction, impairment of long-term
potentiation (LTP), Ca2 dysregulation, mitochondrial dys-
function, endoplasmic reticulum stress, and the activation of
pro-apoptotic pathways leading to cell death (4, 5). Various
oligomeric forms of A have been isolated from human AD
brain and from the brains of ADmodelmice, as well as from cell
culture medium, in addition to being produced from prepara-
tions of recombinant or synthetic A peptides (6–10). Almost
certainly, preparations of AO, whether isolated from natural
sources or produced in vitro, are composed of a number of
oligomeric species with diverse biophysical and biological
properties existing in dynamic equilibrium (6, 11). This
dynamic equilibrium complicates studies when attempting to
isolate a particular population of oligomers, e.g. by size exclu-
sion chromatography, as the resultant “purified” oligomer
preparation will remodel to other species as the preparation
resets its equilibrium.Therefore, it is not surprising that there is
controversy over which is the toxic form of AO, and indeed
whether there is a single toxic entity (6).
The conformation of AO aggregates has emerged as a use-
ful classification method that is more biologically relevant than
size, given that the structural motifs present on the surface of a
protein will determine its binding partners and biological activ-
ities. Various conformation-specific antibodies that react with
AO have been produced and characterized (reviewed in Ref.
6). Two of the more widely used conformation-specific anti-
bodies are the A11 andOC antibodies (12, 13), which recognize
mutually exclusive structural epitopes on a range of amyloid-
forming proteins, not just A, independent of primary amino
acid sequence. A11 antibodies recognize out-of-register anti-
parallel  sheet structures, whereas OC antibodies detect in-
register parallel  sheets (14–16).
A recent study (16) classified brain-derived AO into two
types based in part on their reactivity to these conformation-
specific antibodies. Type 1 AO were A11-immunoreactive
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(also referred to as A*56) and had no temporal, spatial, or
structural relationship to amyloid fibrils, whereas type 2 AO
recognized by OC antibodies were related to amyloid fibrils
temporally, spatially, and structurally and represented the
majority of oligomers generated in vivo. The authors con-
cluded that although most of the soluble A in brains with
dense core plaques (e.g. AD brains) are type 2 AO, the bulk
of these oligomers are rendered functionally innocuous by
their effective containment within plaques. In contrast, they
suggested that type 1 AO may be more directly pathogenic
in certain brain regions as they are more finely dispersed
than the type 2 AO (16). Further work is required to recon-
cile these conclusions with the observations that OC reactiv-
ity, not A11 reactivity, correlated with the onset and severity
of AD in human brain studies (17, 18) and that only OC-
positive oligomers correlated with cognitive decline and
promoted tau aggregation and phosphorylation in a different
transgenic AD mouse model (18).
Another recent study (19) utilized several oligomer-directed
quantitative assays, including a high specificity binding assay
based on the affinity of certain AO for the cellular form of the
prion protein (PrPC) (PrP-ELISA or PLISA) (20), to assay AO
across brain tissue frommultipleADmousemodels and human
brain samples. The PrPC-interacting AO represented a dis-
tinct population of high molecular weight A assemblies that
were as accurate as any other predictor of memory impairment
in the AD mouse models and human AD patients. Oligomers
interacting with PrPC were preferentially recognized by theOC
antibody rather than the A11 antibody (21, 22) and thus would
appear to correspond to the type 2 AO (16). Critically, the
fraction of PrPC-interacting AO varied greatly between trans-
genic AD mouse models and likely determines the extent to
which PrPC-dependent molecular mechanisms contribute to
the progression of AD (19). That different transgenic AD
mousemodelsmay produce predominantly one (or a few) of the
many potential types of AO present in the human AD brain
clearly complicates interpretation of data from the animal
models. More work is required to clarify these discrepancies in
AO type and function both between animal models and
between the animalmodels and the human situation. However,
the characterization of different AO species based on anti-
body or other conformational recognition (e.g. PrPC interac-
tion) is a useful criterion with which to help decipher the
contribution of particular oligomeric species to AD patho-
genesis. In vivo it is highly likely that more than one oligo-
meric species contributes to toxicity, and thus understand-
ing the temporal and spatial distribution of all AO types in
the brain during the initiation and development of AD, as
well as knowing their receptors and mechanisms of toxicity,
is essential to progress the field. Although AO have been
proposed to cause neurotoxicity through a variety of mech-
anisms, including direct interaction with lipids resulting in
damage to the membrane through, for example, pore forma-
tion, or through intracellular accumulation leading to cyto-
toxicity (23, 24), here we focus on the binding of A to cell
surface receptors.
FIGURE 1. A receptors and their cellular locations. A monomers aggregate into oligomers and fibrils in the brain, interacting with a variety of
receptors on the presynaptic and postsynaptic membranes of neurons, on endothelial cells, and on astrocytes and microglia. The endothelial receptors
RAGE and LRP1 are involved in A monomer clearance through the blood-brain barrier. LRP1 also mediates monomer efflux into astrocytes. The
microglial receptors Scara1/2 and MARCO are linked to A clearance by interaction with fibrillar A. Oligomeric A is widely viewed as the pathogenic
species, triggering synaptic impairment and cell death following interaction with a range of postsynaptic neuronal receptors, including EphB2, PrPC,
and 7nAChR, which are linked to NMDAR dysfunction. AO also bind to EphA4, LilrB2, Frizzled (Fzd), and PGRMC1 receptors, triggering synaptic
impairment. In addition, AO bind to the presynaptic receptors 7nAChR and NaK3, which are linked to altering presynaptic calcium levels. See text
and Table 1 for details.
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The “Good” A Receptors
Proteins that bind A (whether monomeric, oligomeric, or
fibrillar forms) and reduce the amount available to aggregate
into toxic oligomers can in many ways be considered “good”
receptors. Such receptors may internalize A into neurons or
other cells (e.g. microglia) and target it for lysosomal degrada-
tion or remove it from the brain by transcytosis across the
blood-brain barrier (BBB) (Fig. 1). One such receptor is the
low-density lipoprotein receptor-related protein 1 (LRP1),
which binds multiple ligands including monomeric A and is
abundantly expressed in various brain cell types. LRP1 has been
implicated inmediating A transcytosis across the BBB (25), as
well as in the uptake and local clearance of A in vascular
smooth muscle cells and neurons (26, 27). Recently, the AD
genetic risk factor PICALM, which encodes the phosphatidyli-
nositol-binding clathrin assembly (PICALM) protein involved
in the endocytosis of various cell surface receptors, was
reported to influence A clearance across the BBB through
regulating the function of LRP1 in brain endothelial cells (28).
PrPC has also been linked to A transport across the BBB (29).
PrPC on endothelial cells boundmonomeric A40, and genetic
knock-out or the addition of a competing PrPC antibody
blocked the transcytosis of A40 in a process that also required
LRP1 (29). The low-density lipoprotein receptor (LDLR) is also
implicated in neuronal and astrocytic A uptake and BBB tran-
scytosis of A (30). Although not cell surface receptors, the
carriers apolipoprotein (apo) E and clusterin (apoJ) bind soluble
A and facilitate its uptake through receptors such as LRP1 or
LRP2 and LDLR, thereby reducing the amount of A available
to aggregate (31). Microglial cells surrounding A plaques
express the scavenger receptors SCARA1 and SCARA2, which
have a high affinity for soluble and fibrillar A and mediate
phagocytosis and clearance of A from the brain (32). The
macrophage receptor with collagenous structure (MARCO)
binds A and activates the ERK1/2 signaling pathway, leading
to reduced inflammation (33). Collectively, these and other
receptors and carriers (Table 1) work together, alongside other
mechanisms for degrading or inactivating A in the extracellu-
lar environment, such as the A-degrading enzymes neprilysin
and insulin-degrading enzyme (34), to maintain A at low,
manageable, non-toxic levels in the brain.
The “Bad” A Receptors
In contrast to the “good” receptors described above that pro-
mote the transcytosis of A out of the brain, onemechanism of
action of the “bad” receptors is tomediate the uptake of A into
the brain across the BBB. The receptor for advanced glycation
end products (RAGE), present on endothelial cells, mediates
the influx of circulating A (35). RAGE also internalizes A
into neurons, promoting its intracellular aggregation and accu-
mulation, leading to rapid activation of p38 MAPK and mito-
chondrial dysfunction (36). Contributing to the accumulation
TABLE 1
A receptors and carriers
The A receptors and soluble carrier proteins are classified into “good” receptors that promote the clearance or degradation of A, thereby lowering the amount available
to form AO, and into “bad” receptors that mediate the neurotoxic actions of AO. See text and supplemental Table I for more details. AMPAR, -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor; VLDLR, very low-density-lipoprotein receptor.
A receptors and carriers A type/conformation Other interactors Reference
“Good” receptors
7-Nicotinic acetylcholine receptor ( 7nAChR) A42 monomer/LMW oligomers (4–24 kDa) 79
Apolipoprotein E (apoE) A40/42 monomer LRP1, LDLR 31
Clusterin (ApoJ) A40 monomer LRP2 80
Complement receptor type 3 (CR3 or Mac1) A40/42 fibrillar SR-A 81
Formyl peptide receptor (FPR1)/formyl-peptide receptor-like 1 (FPRL1) A42 81
Heparan sulfate proteoglycan (HSPG) A40/42 monomer LRP1 82
Low-density lipoprotein receptor (LDLR) A40/42 monomer apoE 83
Low-density lipoprotein receptor-related protein 1 (LRP1) A40/42 monomer PICALM, apoE 25–28
Macrophage receptor with collagenous structure (MARCO) A42 monomer FPRL1 33
Phosphatidylinositol-binding clathrin assembly (PICALM) protein A40/42 monomer Clathrin/LRP1 28
Prion protein (PrPC) A40 monomer LRP1 29
Scavenger receptors (SCARA1/2) A42 fibrillar 84
“Bad” receptors
7nAChR A42 oligomers (4–56 kDa) 85
AMPA receptor A42 ADDLs (8–40 kDa) A11-negative 86
Amylin 3 receptor (AMY3) A42 ADDLs (4–96 kDa) 87
apoE A40/42 oligomers VLDLR/LRP1 31, 88
2 adrenergic receptor (2AR) A42 dimer GluR1 (AMPAR) 89
Clusterin (ApoJ) A42 oligomer (8–200 kDa) 90
Ephrin A4 (EphA4) A42 oligomers (4–100 kDa) 91
Ephrin B2 (EphB2) A42 ADDLs (LMW) NMDAR, PSD95 55, 58
Fc receptor IIb (FcRllb) A42 ADDLs (LMW) 92
Frizzled (Fzd) A40/42 ADDLs (12–96 kDa) 93
Insulin receptor A42 ADDLs (50–100 kDa) 94
Leukocyte immunoglobulin-like receptor B2 (LilrB2)/PirB A42 ADDLs (50–150 kDa) 95
Na/K-ATPase neuron-specific 3 subunit (NaK3) ASPD (128 kDa spheres) 38
Neuroligin-1 A42 A11-positive PSD95 96
NMDA receptor A42 ADDLs (12–96 kDa) PSD95 10, 55, 57
p75 neurotrophin receptor (p75NTR) A42 ADDLs (LMW) DR6 97
P/Q-type calcium channels A42 globulomers 98
PrPC A42 ADDLs (70–250 kDa) OC-positive mGluR5, LRP1 20, 21, 43, 48
Receptor for advanced glycation end products (RAGE) A40/42 monomer 99
SCARB2/ CD36 Fibrillar A TLR-4, TLR-6 100
Sigma-2/PGRMC1 A42 oligomers (50–75 kDa) 74, 77
Toll-like receptor 2 (TLR2) A42 fibrillar 81
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of A in the brain is apoE4, a well established genetic risk factor
for the development of late-onset AD. As well as being involved
inmodulating the clearance and degradation of A in the brain,
apoE also slows the transport of A across the BBB in an
isoform-dependent manner, with apoE4 having the greatest
effect (37). The detrimental effects of apoE4 are further exacer-
bated by its ability to bind to and stabilize AO, slowing down
their transition to fibrils (37).
When the first AO were prepared from synthetic A42
peptide, the now widely used A-derived diffusible ligands
(ADDLs), it was observed that their binding to hippocampal
neurons was abolished by treating the cells with trypsin (7).
This observation, coupled with the low oligomer concentration
(5 nM) required for neurotoxicity, indicated that one or more
high-affinity protein receptors are responsible for AObinding
and subsequent neurotoxicity. To date, several candidate “bad”
A receptors that bind AO at the cell surface and then trigger
a variety of downstream signaling pathways that negatively
impact on neuronal function and survival have been described
(Table 1; supplemental Table 1) (38–41). The role of several of
these receptors in mediating AO neurotoxicity is controver-
sial or yet to be reproduced. The heterogeneity and dynamic
nature of AO preparations as discussed above undoubtedly
have led to difficulties in first identifying a particular receptor
and then in corroborating its involvement in different model
systems and between different laboratories. The use of different
and often poorly characterized preparations of AO, different
toxicity measurements on divergent target cell populations
under different conditions, and the use of different transgenic
AD mouse models at different stages of disease all confuse the
picture. The recent report that the proportion of PrPC-interact-
ing AO varies between different mouse models of AD (19)
may go some way to explain these discordant observations.
Indeed this highlights a fundamental issue in the field; it is very
unlikely that all receptors bind to the sameoligomeric species of
A, and binding of different AO to an individual receptormay
be differentially influenced by other receptors or co-receptors
in their vicinity (see below). Many of the signaling pathways
initiated by these receptors converge into common down-
stream targets that are ultimately responsible for neurotoxicity
and cell death.
Dynamic Signaling PlatformsMediate AO Binding and
Action
Various lines of evidence suggest that AO binding to neu-
rons may involve multi-protein cell surface receptor com-
plex(es) whose assembly is initiated upon binding of oligomers
to one or more of the receptor proteins listed in Table 1. These
signaling platforms or signalosomes (5, 39, 42) will be formed
fromcomplexes of proteins and lipids in the plane of the plasma
membrane, andwill be transient in nature and likely involved in
both physiological and pathological responses, contributing to
both neuroprotection and neurotoxicity. The relative contri-
bution to these two endpoints may depend on multiple fac-
tors, including the type and concentration of oligomer spe-
cies, the compartmentalization of particular receptors and
signaling effectors into different signaling platforms, the rel-
ative local interaction and concentration of particular recep-
tors, co-receptors, and lipids, the interplay between the
various downstream signaling pathways, and the rate of
receptor down-regulation/internalization.
One such signaling platform is based on PrPC (Fig. 2A). PrPC
was identified to bind AO, but not monomers or fibrils, with
high affinity (Kd 0.4 nM) (43, 44) and to selectively interact
with high molecular mass assemblies of AO in AD but not
control brains (45). PrPC was responsible for the AO-medi-
ated inhibition of LTP in hippocampal slices (43) and was also
required for the manifestation of memory impairments in an
ADmousemodel (46). AObinding to PrPC leads to activation
of Fyn kinase, which in turn phosphorylates the GluN2B sub-
unit ofN-methyl-D-aspartate receptors (NMDARs), which was
coupled to an initial increase and then a loss of surface
NMDARs (20). In addition, the AO activation of Fyn leads to
tau phosphorylation (47). Both mGluR5 (48) and LRP1 (21)
have been identified as co-receptors required for the PrPC-
bound AO to activate Fyn (Table 1).
PrPC localizes to cholesterol- and sphingolipid-rich, deter-
gent-resistant lipid rafts due to the saturated acyl chains in its
glycosylphosphatidylinositol anchor and to an N-terminal tar-
geting signal interacting with the heparan sulfate proteoglycan,
glypican-1 (49, 50). PrPC has been proposed as a key scaffolding
protein for the dynamic assembly of cell surface signalingmod-
ules (51), and PrPC, along with the microdomain-forming flo-
tillin or caveolin proteins, may lead to the local assembly of
membrane protein complexes at sites involved in cellular com-
munication, such as cell-cell contacts, focal adhesions, the
T-cell cap, and synapses (52). The integrity of lipid rafts is crit-
ical for the cell surface binding of AO and the subsequent
activation of Fyn. Treatment of cells with methyl--cyclodex-
trin, which depletes cellular cholesterol and thus disrupts the
cholesterol-rich lipid rafts, caused the re-localization of PrPC
and Fyn from detergent-resistant rafts to detergent-soluble,
non-raft regions of themembrane (21). Surprisingly, disruption
of the rafts with methyl--cyclodextrin significantly reduced
(by80%) the cell surface binding of theAO, although the cell
surface expression of PrPC was unaffected, and prevented the
AO from activating Fyn (21). The addition of AO to neurons
caused a large increase of mGluR5 in the detergent-resistant
fraction (53), and on binding oligomers, the co-localization of
LRP1 and PrPC increased (21), suggesting that binding of AO
to PrPC causes these co-receptors to cluster together in rafts
and activate the signaling complex. This cell-surface, raft-based
signaling complex based on PrPC may be key in mediating the
neurotoxic actions of type 2 AO (Fig. 2A). Another cholester-
ol-rich, raft-based platform may involve the presynaptic
7-nicotinic acetylcholine receptor (7-nAChR) as its AO-
mediated activationwas attenuated ondisruption of the rafts by
cholesterol depletion (54).
Another signaling platform(s) is likely based on NMDARs
(Fig. 2B), which are necessary but not sufficient for AO bind-
ing (reviewed in Ref. 5). NMDARs are anchored by PSD95,
which acts as a scaffold to organize multiple membrane-associ-
ated proteins at synapses and which interacts with other AO
receptors including EphB2 (55). Binding of AO to postsynap-
tic density complexes containing NMDARs promoted den-
dritic spine loss in an NMDAR-dependent manner and abol-
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ished NMDAR-dependent LTP (55, 56). Antibodies against the
subunits of NMDAR blocked the binding of AO to neurons,
and the NMDAR antagonist Memantine completely protected
against AO-induced reactive oxygen species formation (57),
indicating that the receptors are required for binding and
downstream action of AO. However, no direct binding of
AO to NMDAR subunits has been reported. The EphB2
receptor modulates NMDAR by tyrosine phosphorylation and
recruits active NMDAR to excitatory synapses. AO interacted
directly with the extracellular fibronectin repeats of EphB2,
which led to depletion of surface EphB2 by enhancing its pro-
teasomal degradation and to the internalization of GluN1 sub-
unit-containing NMDARs (58). The 7-nAChR also induces
AO-mediated NMDAR dysfunction and synaptic impair-
ment. 7-nAChR binds AO with high affinity, and binding
leads to activation of the channel, increased cytosolic Ca2, and
subsequent activation of protein phosphatase 2B (PP2B).
De-phosphorylation of the tyrosine phosphatase striatal-
enriched protein tyrosine phosphatase (STEP) via PP2B pro-
motes STEP to dephosphorylate Tyr-1472 on the NMDAR
subunit GluN2B, thereby disrupting its binding to PSD95, ulti-
mately leading to the internalization of the receptor (59). Thus,
binding of AO (possibly distinct species) tomultiple receptors
promotes neurotoxicity via NMDAR. Although both EphB2
and 7-nAChR mediate AO action via NMDARs, whether
they are located in the same signaling platform awaits to be
determined. Although binding of AO to PrPC also results in
altered NMDAR function, EphB2 does not link AO-PrPC
complexes to Fyn activation (48), providing clear evidence for
the existence of distinct AO-binding signaling platforms.
A further signaling platform is based on theNa/K-ATPase
(Fig. 2C), whose neuron-specific 3 subunit (NaK3) was
recently identified to bind amylospheroids (ASPD) (38). ASPD
are 15-nm spherical AO that are distinct from ADDLs, that
are not recognized by the A11 conformation-dependent anti-
body, and that caused selective degeneration of mature human
neurons (60). The direct binding of ASPD to NaK3 impaired
its activity, resulting in an increase in cytoplasmic Na and
depolarization of the neuron. This in turn activated N-type
voltage-gated Ca2 channels (N-type VGCC), leading to Ca2
overload in the cytoplasm andmitochondria, ultimately leading
to tau phosphorylation and degeneration of neurons. This sig-
naling platform is localized on the presynaptic membrane
(Fig. 1).
Further signaling platforms, based on other groupings of the
receptors in Table 1, possibly in association with distinct com-
binations of membrane lipids, may be involved in binding the
same and/or other oligomeric forms of A and transducing
neurotoxic signals. It should also be noted that although we
have described these different signaling platforms as distinct
entities (Fig. 2), it is possible that they are not structurally or
functionally isolated and that “super” platforms exist which
containmultiple receptors interactingwithmultiple oligomeric
forms of A. Furthermore, the protein and lipid composition of
these dynamic signaling platforms may alter as a result of elec-
trophysiological activity, oxidative damage, changes in lipids
FIGURE 2. A oligomer receptor signaling platforms. AO induce synaptic impairment and neuronal cell death by interacting with multiple receptor
signaling platforms. A, PrPC-based, cholesterol- and sphingolipid-rich lipid raft signaling platform. The co-receptors LRP1 andmGluR5 cluster with PrPC upon
AO binding and lead to activation of Fyn kinase, which phosphorylates NMDAR and tau. pTyr18, phospho-Tyr-18; pTyr1482, phospho-Tyr-1482. B, both
7nAChR and EphB2 bind AO and induce NMDAR-mediated dysfunction and synaptic impairment. pCREB, phospho-cAMP-response element-binding
protein. C, the presynaptic NaK3 binds ASPD oligomers, inducing Ca2 influx via N-type VGCCs, resulting inmitochondrial dysfunction, tau phosphorylation,
and synaptic impairment.
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such as reduced cholesterol, hypoxia, and other cellular activi-
ties, and insults that are known to influence the initiation
and/or progression of AD, thus influencing AO binding and
the downstream signaling pathways that are activated.
Does the AO-promoted clustering of receptors lead to the
induction of aberrant neurotoxic signaling (53) or over-stimu-
lation of a physiological pathway (for example, due to pro-
longed stabilization of an otherwise transient complex involved
in normal signaling processes), i.e. gain of toxic function? Or is
it the hijacking of the signaling platform by AO that disrupts
normal physiological signaling, i.e. loss of function? Or a com-
bination of these that leads to the neurotoxicity apparent in
AD? The amount and/or activity of, and interactions between,
individual signaling platform components are likely finely bal-
anced. Either an increase or a decrease in a particular compo-
nent or an alteration in the interaction between components
may be sufficient for AO to trigger neurotoxicity. It is possible
that it is the binding of different AO to multiple signaling
platforms that initiates the complex series of events underlying
AD. Following on from this, in the transgenic mouse models
that predominantly produce only one type of AO (19), not all
of these signaling platforms will be engaged, resulting in activa-
tion of only some of the downstream signaling pathways and
thus not recapitulating the complete array of molecular, cellu-
lar, and pathological responses seen in the human disease.
Therapeutic Approaches to Blocking AOAction
AO and their cell surface receptors provide a multitude of
potential therapeutic targets (Fig. 3). For example, the accumu-
lation of the “toxic” AO could be prevented by blocking their
formation, promoting their aggregation into larger order
“inert” fibrils or plaques, altering their conformation, or induc-
ing their clearance or degradation (Fig. 3, a–d). Immunother-
apy is being actively explored as a potential means to reduce A
levels in the brain, although results from several clinical trials
have been disappointing (61). Whether natural antibodies or
other antibody preparations that bind to conformational
epitopes onAOand are therefore selective forAOover other
forms of A will be more effective than antibodies that recog-
nize peptide epitopes and thus bind both monomeric and olig-
omeric forms of A awaits to be seen (62–64). The polyphe-
nols, resveratrol and ()epigallocatechin-gallate (EGCG)
convert soluble AO into non-toxic aggregates (65, 66) whose
binding to PrPC is severely impaired and which no longer acti-
vate Fyn (21). Another natural compound, brazilin, has recently
been identified to potently remodel mature fibrils, preventing
the formation of toxic oligomers by secondary nucleation (67).
As clearance of A across the BBBmay be impaired in AD (68),
approaches to increase transcytosis of A out of the brain may
hold potential. In this respect, a soluble formof LRP1 promoted
A clearance in a transgenic AD mouse model (69).
Another approach is to prevent the initial interaction ofAO
with its receptor or to displaceAOthat are already bound (Fig.
3, e and f). Following identification of PrPC as a high affinity
receptor forAO(43), immuno-targeting of PrPCwas shown to
block completely the LTP impairments caused by AOderived
fromhumanADbrain extracts (70, 71), and intra-cerebral infu-
sion of an anti-PrPCmonoclonal antibody reversed thememory
impairments in a transgenic AD mouse model (72). Recently,
the small molecule Chicago Sky Blue 6B was identified in a
high-throughput screen to bind to PrPC and inhibit AO bind-
ing (73). Sigma-2/PGRMC1 was identified as a receptor medi-
ating the binding and toxicity of both brain-derived and syn-
thetically prepared AO following the screening of a library of
CNS drug-like small molecules that blocked AO-induced def-
icits (74). The compounds identified were ligands for Sigma-2/
PGRMC1 and prevented AO from binding to primary hip-
pocampal neurons and also displaced bound oligomeric
species. The smallmolecule rhynchophyllinewas identified as a
novel inhibitor of EphA4, which blocked the ligand-binding
domain of EphA4 and rescued AO-induced deficits (75). Sur-
face epitopemasking peptides have recently been shown to pre-
ventASPD interactingwithNaK3 (38) (Fig. 3g). Tetrapeptides
mimicking the binding region of this receptor bound to the
surface of ASPD, subsequently blocking their interaction with
the receptor and preventing ASPD-induced impairments but
without affecting the normal function of the Na/KATPase
(38).
Complete blocking of receptors may have deleterious effects
on neuronal function; however, modulating receptor activity is
another potential approach to abrogate AO action (76) (Fig.
FIGURE 3. Potential targets for therapeutic intervention in A oligomer
receptor signalingplatforms. The toxic actions of AOcanbepreventedby
multiple approaches. Their accumulation canbepreventedbypromoting the
clearance/degradation of A monomers (a), preventing aggregation (b),
remodeling “toxic” conformations (c), or promoting aggregation to inert
fibrils or plaques (d). AO action at the cell surface can be targeted by block-
ing their binding to receptors (e), displacing bound AO (f), or masking the
epitope on the oligomers to prevent binding to their receptor (g). The recep-
tors themselves can be targeted either by preventing aberrant clustering of
receptorsmediated by AO (h) or by allostericallymodulating receptor activ-
ity (i). Downstream signaling of AO can be targeted by modulating kinase/
phosphatase activity (j) in thedownstreamsignal transductionpathways. See
text for specific examples of each.
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3h). Antagonism of the mGluR5 receptor using negative allos-
teric modulators prevented AO-induced spine loss and cog-
nitive deficits in transgenic mice (48). The Sigma-2/PGRMC1
ligands also acted as allosteric antagonists for the receptor, pre-
venting aberrant signaling, as well as the subsequent spine loss
and cognitive impairments in AD transgenic mice (77).
Another approach is to target the downstream signal transduc-
tion pathways activated uponAObinding to its receptors (Fig.
3i). For example, given that AObinding to PrPC activates Fyn,
a Phase 1b trial of a potent small molecule inhibitor of Src and
Fyn for the treatment of AD is underway (78). Ultimately, a
combined therapeutic approach, targetingmore than one AO
species, its receptor(s), and/or its downstream signaling path-
way, will likely be required to alleviate all the neurotoxic effects
of the multiple oligomeric forms of A.
Concluding Remarks
Although much progress has been made in identifying A
receptors, several questions remain unanswered. How many
distinct AO receptors and signaling platforms are there?
What is the contribution of each receptor and signaling plat-
form to AO-mediated toxicity? What are the individual com-
ponents in each signaling platform, and how do their composi-
tions, as well as the interactions between them, differ between
AD and healthy individuals? Are different AO signaling plat-
forms involved depending on the initial trigger of disease, and
what is their spatial and temporal contribution to disease
pathogenesis? Given that there are multiple species of AO,
and that some transgenic mouse models appear to have pre-
dominantly one type of AO, each interacting with a distinct
set of receptors, what is the most appropriate animal model?
How can we target specific signaling platforms for therapeutic
intervention inADwithout disrupting the normal physiological
roles of these signaling complexes? Answers to these questions
will come only from further experimental work comparing the
binding of defined AO preparations (characterized on the
basis of biophysical and conformational properties) with each
of the identified receptors in situ on cells and in vivo in appro-
priate animal models. However, the recognition that there are
multiple A receptors, binding different forms of A, possibly
preferentially in different stages in the development of AD, pro-
vides several opportunities for therapeutic intervention as
highlighted here.Whatmust also be recognized is that not only
are there “bad” A receptors binding oligomeric forms of A
and triggering cytotoxicity, but there are also “good” receptors
involved in A clearance and metabolism, as well as some like
PrPC that may play dual roles.
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